TargetGene was founded in 2012 by Drs. Dan Weinthal and Yoel Shiboleth following their 2011 invention of RNA-guided nucleases for genome editing. This was in the pre-CRISPR days and potential investors were inclined to dismiss RNA-guided nucleases as unachievable science fiction…
Our first investors were in the agricultural field, Adama and Monsanto, but since those days we have raised funding from a multinational CDMO and have transitioned to therapeutics. TargetGene has licensed some applications of the platform, and is now partnering with a therapeutics company. In 2019 TargetGene has also been the recipient of a grant from the Israel Innovation Authority.
We have just achieved our goal of creating the world’s best working genome editing platform. Our patent has recently been granted in the US following grants in many other jurisdictions. For TargetGene the time is perfect, and competing technologies have paved the way forward in the market.